March 30, 2022 5:00pm
Tuesday’s headwinds decreased the upsides while macro elements slowly infect sentiment
Pre-open indications: 10 Hits and 1 MISS
The Biostage (BSTG) Chronicles: closed up +$0.50 with 3,926 shares traded after Tuesday’s -$0.50 with 3,330 shares traded after Monday’s +$0.25 with 13,012 shares traded. A 3-year-old IND, no clinical trial, a terminal death suit – who’s putting pricing “lipstick” on this pig?
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
The metrics say it all … just the facts
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -65.38 points (-0.19%); the S&P closed DOWN -29.15 points (-0.63%) while the Nasdaq closed DOWN -177.36 points (-1.21%)
Henry’omics:
Indexes moved lower on Wednesday after rallying in the previous session as Ukraine invasion continued and the bond market’s 5 and 30-year Treasury yields inverted Monday for the first time since 2016.
- Historically, this inversion has been a sign of a coming recession, though it hasn’t been a good indicator of when the recession would come. Still, investors largely shrugged off the event. <CNBC>
- Economic Date Docket: The ADP payrolls report said private firms added 455,000 jobs in March. Economists were expected 450,000. The final reading for Q4 U.S. GDP showed 6.9% growth, below the preliminary reading of 7%.
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Wednesday opened negative at 16 up/17 downs, 2 flats; flipped positive at the mid-day at 18/16 and 1 flat, ending with a negative close of 7/28;
All-time low:
- Applied Genetic Technologies (AGTC) $1.10
Pre-open Indications: 10 Hits < Alnylam Pharmaceuticals (ALNY -$1.50), Beam Therapeutics (BEAM -$2.58), Caribou Biosciences (CRBU -$0.20), CRISP Therapeutics (CRSP -$1.87), Editas Medicine (EDIT -$0.92), BioLife Solutions (BLFS +$0.25), Fate Therapeutics (FATE -$2.08), Intellia Therapeutics (NTLA -$4.05), Ultragenyx (RARE -$0.13), Sage Therapeutics (SAGE -$1.02)> 1 Miss < Biostage (BSTG +$0.50 with 3,926 shares traded after Tuesday’s -$0.50 with 3,300 shares traded),
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 … (VSTM, BCLI & ADVM) added with 34 to date
Key Metrics:
- Wednesday - Sector volume was LOW with 3 of the 7-upside having higher than the 3-month average volume with LOW volume of 3 of 28-downside having higher than the 3-month average volume;
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday, the IBB was down -1.31% and the XBI was down -3.07%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was up +0.40 points or +2.12% at 19.30
Jumping with share pricing momentum (7 of 7):
- Biostage (BSTG +$0.50 with 3,926 shares traded after Tuesday’s -$0.50 with 3,330 shares traded after Monday’s +$0.25 with 13,012 shares traded),
- Voyager Therapeutics (VYGER +$0.25 after Tuesday’s -$0.90 and Monday’s -$0.97),
- Chinook Therapeutics (KDNY +$0.12)
- BioLife Solutions (BLFS +$0.25 after Tuesday’s +$1.49 and Monday’s +$0.30),
- Bellicum Pharmaceuticals (BLCM +$0.03),
- Pluristem (PSTI +$0.04),
- Brainstem Cell Therapeutics (BCLI +$0.03),
Hammered in today’s market (10 of 28):
- Intellia Therapeutics (NTLA -$4.05 after Tuesday’s +$3.15 and Monday’s +$2.43),
- Beam Therapeutics (BEAM -$2.58 after Tuesday’s +$2.97 and Monday’s +$1.03),
- Fate Therapeutics (FATE -$2.08 after Tuesday’s +$3.94),
- CRISPR Therapeutics (CRSP -$1.87 after Tuesday’s +$3.12 and Monday’s +$0.69),
- Alnylam Pharmaceuticals (ALNY -$1.50 after Tuesday’s +$5.09 and Monday’s -$2,16),
- Sage Therapeutics (SAGE -$1.02 after Tuesday’s +$1.59 and Monday’s +$1.29),
- Editas Medicine (EDIT -$0.92 after Tuesday’s +$1.68),
- Ionis Therapeutics (IONS -$0.79),
- Global Blood Therapeutics (GBT -$0.64),
- Vericel (VCEL -$0.36 after Tuesday’s +$2.28 after Monday’s +$1.52),
March, Q1/2022:
- Wednesday closed negative with 7 incliners and 28 decliners
The BOTTOM LINE: Follow the bouncing cell and gene therapy sector closes:
- Wednesday closed negative with 7 incliners and 28 decliners
- Tuesday closed positive with 32 incliners and 3 decliners
- Monday closed negative with 13 incliners, 20 decliners and 2 flats
- Friday closed negative with 7 incliners and 28 decliners
- Thursday closed positive with 28 incliners, 6 decliners and 1 flat
- Wednesday closed negative with 6 incliners, 28 decliners and 1 flat
- Tuesday closed positive with 31 incliners and 4 decliners
- Monday closed negative with 2 incliners, 31 decliners and 2 flats
- Friday closed positive with 28 incliners and 5 decliners and 2 flats
Can’t blame this on investors … my dog named “algorithm” chewed the portfolio!
As I stated this a.m., “It wouldn't be surprising to see this market rally thaw and cell and gene therapy sector slip.”
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Also, the month of March is about to end ...
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
